In a parallel study, the endogenous presenilin proteins in fibroblasts were localized to the centrosomes, the nuclear envelope, and its associated interphase kinetochores. Together these results indicate that the presenilin proteins may be involved in mitosis and that FAD mutations in the presenilin genes may predispose to chromosome missegregation (nondisjunction). The data reported here also suggest that trisomy 21 mosaicism may contribute to other forms of AD that are not caused by a presenilin mutation. 1999 Academic Press
An important clue to the cause of Alzheimer's disease (AD) was the discovery that Down syndrome patients who live beyond the age of 30 or 40 develop neuropathology indistinguishable from that observed in AD (Olson and Shaw, 1969; Glenner and Wong, 1984; Wisniewski et al., 1988) . The implication of this finding is that trisomy for chromosome 21-the pathogenetic cause of Down syndrome-leads to AD later in life (for review, see Epstein, 1990) . One possible explanation for the link between Down syndrome and AD is that one or more genes on chromosome 21 are overexpressed-due either to the 50% increased gene dosage present in Down syndrome or to somatic or inherited mutation or localized chromosome duplication in AD, as proposed by Schweber (1985 Schweber ( , 1989 . Indeed, the gene for amyloid precursor protein (APP; the source of the A␤ peptide, which is the major component of the pathological amyloid deposits found in AD brain) resides on chromosome 21 and is overexpressed in Down syndrome individuals (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 1987; Neve et al., 1988; Rumble et al., 1989; Oyama et al., 1994) . Although there is no evidence for localized duplication of part of chromosome 21 in any cases of AD, several inherited mutations have been identified in the APP gene (for reviews, see Ashall and Goate, 1994; Schellenberg, 1995) . These mutations apparently
The positive results of this study have been presented at various international symposia, including first at the 1993 Annual Meetings of the American Society of Human Genetics and of the Society for Neuroscience (Am. J. Hum. Genet. 53, 548 and Soc. Neurosci. Abs. 19, 1255) .
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